-
1
-
-
0030856731
-
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
-
Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;5:4593-4599. (Pubitemid 27441066)
-
(1997)
Cancer Research
, vol.57
, Issue.20
, pp. 4593-4599
-
-
Presta, L.G.1
Chen, H.2
O'Connor, S.J.3
Chisholm, V.4
Meng, Y.G.5
Krummen, L.6
Winkler, M.7
Ferrara, N.8
-
2
-
-
20544478429
-
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial
-
DOI 10.1200/JCO.2005.05.112
-
Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23:3697-3705. (Pubitemid 46252464)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.16
, pp. 3697-3705
-
-
Kabbinavar, F.F.1
Schulz, J.2
McCleod, M.3
Patel, T.4
Hamm, J.T.5
Hecht, J.R.6
Mass, R.7
Perrou, B.8
Nelson, B.9
Novotny, W.F.10
-
3
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
DOI 10.1056/NEJMoa032691
-
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342. (Pubitemid 38702844)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.23
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
Berlin, J.7
Baron, A.8
Griffing, S.9
Holmgren, E.10
Ferrara, N.11
Fyfe, G.12
Rogers, B.13
Ross, R.14
Kabbinavar, F.15
-
4
-
-
34248173883
-
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
-
Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-1544.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1539-1544
-
-
Giantonio, B.J.1
Catalano, P.J.2
Meropol, N.J.3
-
5
-
-
33746833739
-
Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: An NCI Treatment Referral Center trial TRC-0301
-
DOI 10.1200/JCO.2005.05.1573
-
Chen HX, Mooney M, Boron M, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center trial TRC-0301. J Clin Oncol. 2006;24:3354-3360. (Pubitemid 46638889)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.21
, pp. 3354-3360
-
-
Chen, H.X.1
Mooney, M.2
Boron, M.3
Vena, D.4
Mosby, K.5
Grochow, L.6
Jaffe, C.7
Rubinstein, L.8
Zwiebel, J.9
Kaplan, R.S.10
-
6
-
-
23944505197
-
Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- And irinotecan-resistant advanced colorectal cancer patients
-
DOI 10.1159/000087285
-
Santini D, Vincenzi B, La Cesa A, et al. Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. Oncology. 2005;69:27-34. (Pubitemid 41207055)
-
(2005)
Oncology
, vol.69
, Issue.1
, pp. 27-34
-
-
Santini, D.1
Vincenzi, B.2
La Cesa, A.3
Caricato, M.4
Schiavon, G.5
Spalletta, B.6
De Seri, M.7
Coppola, R.8
Rocci, L.9
Tonini, G.10
-
7
-
-
0032730143
-
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen
-
Andre T, Bensmaine MA, Louvet C, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol. 1999;17:3560-3568. (Pubitemid 29517928)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.11
, pp. 3560-3568
-
-
Andre, T.1
Bensmaine, M.A.2
Louvet, C.3
Francois, E.4
Lucas, V.5
Desseigne, F.6
Beerblock, K.7
Bouche, O.8
Carola, E.9
Merrouche, Y.10
Morvan, F.11
Dupont-Andre, G.12
De Gramont, A.13
-
8
-
-
0034727063
-
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
-
Irinotecan Study Group
-
Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905-914.
-
(2000)
N Engl J Med
, vol.343
, pp. 905-914
-
-
Saltz, L.B.1
Cox, J.V.2
Blanke, C.3
-
9
-
-
33645284166
-
Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: A single centre phase II trial
-
Vincenzi B, Santini D, Rabitti C, et al. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer. 2006;94:792-797.
-
(2006)
Br J Cancer
, vol.94
, pp. 792-797
-
-
Vincenzi, B.1
Santini, D.2
Rabitti, C.3
-
10
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors
-
European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
11
-
-
0024536437
-
Optimal two-stage designs for phase II clinical trials
-
DOI 10.1016/0197-2456(89)90015-9
-
Simon R. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10. (Pubitemid 19099520)
-
(1989)
Controlled Clinical Trials
, vol.10
, Issue.1
, pp. 1-10
-
-
Simon, R.1
-
12
-
-
33845382806
-
Non parametric estimation from incomplete observations
-
Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
-
(1958)
J Am Stat Assoc
, vol.53
, pp. 457-481
-
-
Kaplan, E.1
Meier, P.2
-
13
-
-
0017365573
-
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
-
Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977;35:1-39. (Pubitemid 8018922)
-
(1977)
British Journal of Cancer
, vol.35
, Issue.1
, pp. 1-39
-
-
Peto, R.1
Pike, C.2
Armitage, P.3
-
14
-
-
0035819924
-
Re: A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer (multiple letters) [4]
-
Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Re: A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. J Natl Cancer Inst. 2001;93:399-401. (Pubitemid 32229387)
-
(2001)
Journal of the National Cancer Institute
, vol.93
, Issue.5
, pp. 399-401
-
-
Buyse, M.1
Thirion, P.2
Carlson, R.W.3
Burzykowski, T.4
Molenberghs, G.5
Piedbois, P.6
-
15
-
-
38349189743
-
Response-independent survival benefit in metastatic colorectal cancer: A comparative analysis of N9741 and AVF2107
-
Grothey A, Hedrick EE, Mass RD, et al. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol. 2008;26:183-189.
-
(2008)
J Clin Oncol
, vol.26
, pp. 183-189
-
-
Grothey, A.1
Hedrick, E.E.2
Mass, R.D.3
-
16
-
-
1842569206
-
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
-
Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30.
-
(2004)
J Clin Oncol
, vol.22
, pp. 23-30
-
-
Goldberg, R.M.1
Sargent, D.J.2
Morton, R.F.3
-
18
-
-
34447121919
-
Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy
-
Dickson PV, Hamner JB, Sims TL, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res. 2007;13:3942-3950.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 3942-3950
-
-
Dickson, P.V.1
Hamner, J.B.2
Sims, T.L.3
-
19
-
-
85013312416
-
Tumor angiogenesis: Therapeutic implications
-
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
-
(1971)
N Engl J Med
, vol.285
, pp. 1182-1186
-
-
Folkman, J.1
-
20
-
-
34447255724
-
Colorectal Clinical Studies Group. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial
-
Seymour MT, Maughan TS, Ledermann JA, et al. Colorectal Clinical Studies Group. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007;370:143-152.
-
(2007)
Lancet
, vol.370
, pp. 143-152
-
-
Seymour, M.T.1
Maughan, T.S.2
Ledermann, J.A.3
|